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KinBACKGROUND Complete revascularization may improve outcomes compared with an infarct-related artery (IRA)-only
strategy in patients being treated with primary percutaneous coronary intervention (PPCI) who have multivessel disease
presenting with ST-segment elevation myocardial infarction (STEMI). However, there is concern that non-IRA PCI may
cause additional non-IRA myocardial infarction (MI).
OBJECTIVES This study sought to determine whether in-hospital complete revascularization was associated with
increased total infarct size compared with an IRA-only strategy.
METHODS This multicenter prospective, randomized, open-label, blinded endpoint clinical trial evaluated STEMI
patients with multivessel disease having PPCI within 12 h of symptom onset. Patients were randomized to either
IRA-only PCI or complete in-hospital revascularization. Contrast-enhanced cardiovascular magnetic resonance (CMR)
was performed following PPCI (median day 3) and stress CMR at 9 months. The pre-speciﬁed primary endpoint
was infarct size on pre-discharge CMR. The study had 80% power to detect a 4% difference in infarct size with
100 patients per group.
RESULTS Of the 296 patients in the main trial, 205 participated in the CMR substudy, and 203 patients (98 complete
revascularization and 105 IRA-only) completed the pre-discharge CMR. The groups were well-matched. Total infarct size
(median, interquartile range) was similar to IRA-only revascularization: 13.5% (6.2% to 21.9%) versus complete revas-
cularization, 12.6% (7.2% to 22.6%) of left ventricular mass, p ¼ 0.57 (95% conﬁdence interval for difference in
geometric means 0.82 to 1.41). The complete revascularization group had an increase in non-IRA MI on the pre-discharge
CMR (22 of 98 vs. 11 of 105, p ¼ 0.02). There was no difference in total infarct size or ischemic burden between treatment
groups at follow-up CMR.
CONCLUSIONS Multivessel PCI in the setting of STEMI leads to a small increase in CMR-detected non-IRA MI,
but total infarct size was not signiﬁcantly different from an IRA-only revascularization strategy. (Complete
Versus Lesion-Only Primary PCI Pilot Study [CvLPRIT]; ISRCTN70913605) (J Am Coll Cardiol 2015;66:2713–24)
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AAR = area at risk
CMR = cardiovascular magnetic
resonance
IRA = infarct-related artery
LGE = late gadolinium-
enhanced
LV = left ventricle/ventricular
MACE = major adverse
cardiovascular events
MI = myocardial infarction
MSI = myocardial salvage index
MVO = microvascular
obstruction
PCI = percutaneous coronary
intervention
PPCI = primary percutaneous
coronary intervention
STEMI = ST-segment elevation
myocardial infarction
T2w-STIR = T2-weighted short
tau inversion recovery
TIMI = Thrombolysis In
Myocardial Infarction
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2714M ultivessel coronary artery diseaseis seen in approximately 40% ofpatients presenting with ST-
segment elevation myocardial infarction
(STEMI) being treated with primary percuta-
neous coronary intervention (PPCI). Clinical
guidelines recommend percutaneous coro-
nary intervention (PCI) to the infarct-
related artery (IRA) only, largely based on
registry data that have suggested increased
risk of adverse events with complete revas-
cularization (1,2) in those patients selected
to receive complete revascularization. How-
ever, 2 recent prospective randomized
controlled trials (PRAMI [Preventive Angio-
plasty in Myocardial Infarction] trial and
the CvLPRIT [Complete Versus Lesion-Only
Primary PCI Trial]), which compared a strat-
egy of complete versus IRA-only revasculari-
zation in PPCI patients with multivessel
disease, have shown a reduction in major
adverse cardiovascular events (MACE) with
complete revascularization (3,4).SEE PAGE 2725The mechanisms leading to improved clinical out-
comes are currently unclear. However, there is concern
that PCI to non-IRAs may be associated with additional
procedural-related infarction (5). Thesewell-described
type 4a myocardial infarctions (MIs) (6) cannot be
detected by conventional enzymatic markers at the
time of PPCI because the associated increases are
relatively small compared with the large rise in en-
zymes caused by the STEMI itself. Cardiovascular
magnetic resonance (CMR) is able to precisely charac-
terize areas of myocardial injury following myocardial
ischemia. Themyocardium at risk becomes edematous
(7), and late gadolinium-enhanced (LGE) imaging al-
lows the accurate detection and quantiﬁcation ofubstudy was funded by the Medical Research Council and manag
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Infarct size (9) andMVO (10)measured onCMRare both
strong medium-term prognostic markers following
PPCI. There are no CMR data as yet in the literature on
patients undergoing complete revascularization for
multivessel disease at the time of PPCI.
The primary aim of the current pre-speciﬁed sub-
study was to assess whether a complete revasculari-
zation strategy, due to causing additional infarcts in
the non-IRA territories, was associated with greater
infarct size than an IRA-only strategy in patients ran-
domized in CvLPRIT. Additionally, we aimed to assess
whether myocardial salvage and myocardial ischemia
at follow-up CMR were different in the 2 groups.
METHODS
STUDY DESIGN. The design and rationale of the study
have been published previously (11). Brieﬂy, CvLPRIT
CMR was a pre-speciﬁed substudy of a multicenter,
prospective, randomized, controlled, open-label clin-
ical trial and with blinded CMR endpoint analysis
(PROBE design) that was conducted in 7 U.K. centers
between May 2011 and May 2014. The inclusion
(PPCI <12 h from symptom onset and angiographic
stenosis in the non-IRA >70% or >50% in 2 orthogonal
views) and exclusion criteria were as for the main trial
(4) with absolute contraindications to CMR imaging as
an additional exclusion. The Trent Research Ethics
Committee (Ref: 11/H0405/4) approved the study,
which was conducted according to the Declaration of
Helsinki. All patients gave written informed consent.
PATIENTS. The ﬂow diagram for patient recruitment
and testing is shown in Figure 1. Eligible patients from
the ﬁrst 286 in the main trial (4) were approached to
participate in the CMR substudy until the target
recruitment (200) was achieved (April 2013). Patients
in the CMR substudy had similar clinical characteris-
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FIGURE 1 Consort Diagram for CvLPRIT CMR
296 Assented and Randomized
150 complete revasc (CR)
141 Complete
6 IRA only
3 IRA only + CABG
146 IRA only
139 IRA Only
6 complete
1 IRA + CABG
141 consented 9 declined consent 128 consented 18 declined consent
43 did not go into
CMR substudy
21 did not go into
CMR substudy
CMR substudy: n=98 (70%) CMR substudy: n=107 (84%)
Analyzable baseline CMRs: n=98 Analyzable baseline CMRs: n=105
9 month CMR
(n=84)
14 did not have
9-month CMR
9 month CMR
(n=80)
25 did not have
9-month CMR
2 patients excluded:
1 incomplete exam
1 non-diagnostic LGE
Standards of Reporting Trials (CONSORT) diagram illustrating recruitment and patient ﬂow. In the topmost boxes are the numbers of patients
randomized to each of the 2 treatment arms (intention to treat) and the number who subsequently received each treatment. CABG ¼ coronary
artery bypass graft; CMR ¼ cardiovascular magnetic resonance; CR ¼ complete revascularization; CvLPRIT ¼ Complete Versus Lesion-Only
Primary PCI Pilot Study; IRA ¼ infarct-related artery; LGE ¼ late gadolinium enhancement.
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2715RANDOMIZATION AND TREATMENT. Eligible pa-
tients presenting with STEMI within 12 h were
randomized, after verbal assent and coronary angi-
ography, but before PCI to the culprit lesion, to either
IRA-only or in-hospital complete revascularization.
Randomization was stratiﬁed by infarct location
(anterior/non-anterior MI) and time to presentation
(>3 or #3 h). PCI was performed according to current
guidelines. Written informed consent for continued
participation in the study was obtained on the day(s)
following the PPCI, once the patient was able to un-
derstand and retain the information.
ANGIOGRAPHIC ANALYSIS. Pre- and post-PPCI epicar-
dial coronary ﬂow was assessed using Thrombolysis
In Myocardial Infarction (TIMI) scoring (12). Collat-
eral ﬂow to the IRA pre-PPCI was graded using the
Rentrop system (13). Quantitative coronary angio-
graphy was undertaken using QAngioXA v1.0 soft-
ware (Medis, Leiden, the Netherlands).CMR IMAGING. CMR was undertaken in 5 of the 7
hospitals recruiting to the main study, using 1.5-T
platforms (4 Siemens Avanto, Erlangen, Germany,
and 1 Philips Intera, Best, the Netherlands). Patients
from the 2 other participating hospitals without
onsite CMR (Derby and Kettering) were scanned at
Glenﬁeld Hospital.
PRE-DISCHARGE CMR. CMR was performed during
the index admission and after non-IRA PCI in those
patients in the complete revascularization group in
whom the procedure was staged. The protocol was
similar to that previously described (14) with the
addition of T2-weighted short tau inversion
recovery (T2w-STIR) imaging for the detection of
edema and is shown in Figure 2, with typical pulse
sequence parameters for the Siemens scanners. A
complete T2w-STIR left ventricular (LV) short-axis
stack was acquired after localizer and long-axis cine
imaging. Gadolinium gadopentate (Magnevist, Bayer,
TABLE 1 Baseline Characteristics of the Main CvLPRIT and CMR Substudy Participants
CvLPRIT
(n ¼ 296)
CMR Substudy
p ValueCR (n ¼ 98) IRA (n ¼ 105)
Age, yrs 64.9  11.6 63.1  11.3 64.1  10.8 0.53
Male 240/296 (81.1) 87 (88.8) 83 (79.0) 0.06
BMI, kg/m2* 27.3 (24.4–30.2) 27.5 (24.6–29.7) 27.5 (24.7–30.6) 0.36
Systolic BP, mm Hg 137.6  27.1 134.7  27.3 140.0  28.0 0.18
Anterior infarct 106 (35.6) 35 (35.7) 37 (37.2) 0.94
eGFR, ml/min/1.73 95.74  34.7 98.2  34.3 93.49  30.7 0.36
Peak CK, IU/l* 1,010 (423.3–1,740) 1,025 (628–1,660) 1,057 (614–1,834) 0.37
Hypertension 105/287 (36.6) 36 (36.7) 37 (35.2) 0.82
Hypercholesterolemia 75/287 (26.1) 28 (28.6) 28 (26.7) 0.76
Diabetes mellitus 39/287 (13.6) 15 (15.3) 13 (12.4) 0.55
Current smoker 87/285 (30.5) 36 (36.7) 28 (28.0) 0.12
Previous MI 12/287 (4.2) 4 (4.1) 4 (3.8) 0.92
Previous PCI 9/287 (3.1) 4 (4.1) 3 (2.9) 0.63
Killip class II–III 24/286 (8.4) 6 (6.1) 10 (9.5) 0.37
Values are mean  SD, n/N (%), n (%), or median (interquartile range), unless otherwise as noted. *Non-normally
distributed data: analyzed after log transformation with independent Student t testing.
BME ¼ black or minority ethnicity; BMI ¼ body mass index; BP ¼ blood pressure; CK ¼ creatine kinase; CMR ¼
cardiovascular magnetic resonance; CR ¼ complete revascularization; CvLPRIT ¼ Complete Versus Lesion-Only
Primary PCI Pilot Study; eGFR ¼ estimated glomerular ﬁltration rate; IRA ¼ infarct-related artery–only revas-
cularization; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
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administered before the short-axis cine stack.
FOLLOW-UP CMR. Follow-up CMR was performed at
9 months (4 weeks) post-PPCI. The protocol for
follow-up CMR was similar to the pre-discharge scan,
but with T2w-STIR imaging omitted and assessment
of reversible ischemia included. First-pass perfusion
imaging in 3 short-axis slices was performed as pre-
viously described (15) following intravenous admin-
istration of 0.1 mmol/kg gadolinium contrast, using
a breath-hold, saturation recovery gradient-echo
pulse sequence. Pharmacological stress was ach-
ieved with intravenous adenosine infusion at
140 mg/kg/min for $3 min. Rest perfusion, with a
further 0.1 mmol/kg of contrast, was performed after
acquiring a short-axis cine stack covering the entire
LV and $10 min after stress imaging. LGE imaging
was acquired 10 min following rest perfusion.
CMR ANALYSIS. Physicians blinded to all clinical
data, including treatment allocation, performed the
CMR analyses at the University of Leicester core lab-
oratory. Image quality was assessed on a 4-point
scale: 3 ¼ excellent; 2 ¼ good; 1 ¼ moderate; and
0 ¼ unanalyzable. Additionally, for T2w-STIR se-
quences, if no regional variation in signal intensity
within the myocardium was seen, these patients were
excluded from analysis of the area at risk (AAR).
LV volumes and mass were calculated from cine
images as previously described using QMass v7.1(Medis) (15). The presence of LGE was assessed by 2
observers (G.P.M., J.N.K.) and was quantitated with
cvi42 (Cardiovascular Imaging, Calgary, Alberta,
Canada) using the full-width half-maximum tech-
nique (16). If infarction was seen in more than 1 cor-
onary territory in the pre-discharge CMR, this was
recorded as being in the IRA territory (associated
edema and/or MVO) or the non-IRA territory with the
consensus of 3 observers (J.N.K., G.P.M., J.P.G.). Non-
IRA infarcts were additionally classiﬁed as likely to be
acute or chronic (presence of wall thinning and no
edema/MVO). Infarct size was recorded for both IRA
and non-IRA LGE, and total infarct size was the sum
of all LGE. Edema (AAR) was quantiﬁed as hyper-
enhancement on T2w-STIR imaging in cmr42 using
Otsu’s Automated Method (17). Areas of hypo-
enhancement within infarct and edema were regar-
ded as MVO and intramyocardial hemorrhage,
respectively, and included in the infarct size and
AAR, respectively. LV volumes and mass were
indexed to body surface area, and infarct size was
expressed as percentage of LV mass. Myocardial
salvage index (MSI) was calculated as the percentage
of the AAR that was not infarcted on LGE images
using infarct size from both the pre-discharge
(Acute MSI) and follow-up (Final MSI) CMR scan.
Perfusion images were visually assessed for defects
(visible defect for $5 heartbeats) by the consensus of
2 observers (J.N.K., G.P.M.). Cine, stress perfusion,
rest perfusion, and LGE images were studied together
and assessed according to the American Heart Asso-
ciation 16-segment model. Rest perfusion images
were used mainly to identify artifacts. Perfusion
defects and areas of infarction were graded as sub-
endocardial (#50% transmurality) or transmural
(>50% transmurality) and given a score of 1 or 2,
respectively, per segment, whereas normal myocar-
dium was scored 0. A modiﬁed summed difference
score was calculated (maximum score 32) (18), deﬁned
as the difference between the sum of segmental stress
perfusion defects and LGE. The summed difference
score was expressed as percentage of the maximum
possible to calculate ischemic burden.
INTRA- AND INTEROBSERVER VARIABILITY OF LV
VOLUMETRICS AND INFARCT CHARACTERISTICS.
Ten pre-discharge and follow-up scans were
randomly selected and analyzed twice by the same
observer after 4 weeks (J.N.K.) and once by a further
observer (S.N.). The data are shown in the Online
Appendix. All intraclass correlation coefﬁcients for
intraobserver and interobserver agreement for CMR
quantitative data exceeded 0.92.
CLINICAL OUTCOMES AND FOLLOW-UP. MACE
comprisedacompositeofall-causemortality, recurrentMI,
FIGURE 2 Pre-Discharge CMR Protocol
T2w-STIR 4C, 2C, 3C, SAX (10 min)
10 mm ST, no gap, matrix 208x256, FOV
300-360x360-420, flip angle 65°, TR 2xRRs, TE
60 ms, turbo-factor (20-40), coil signal
intensity correction on
Edema? (AAR), IMH (hypoenhancement)
Localizers
Cine imaging 4C,2C, 3C (5 min)
8 mm ST, 2 mm gap, matrix 208x256, FOV 300-360
x360-420, flip angle 65°, TR 3.1 ms, TE 1.2 ms
LV, function
Cine imaging SAX stack (10 min)
8 mm ST, 2 mm gap, matrix 208x256, FOV
300-360x360-420, flip angle 65°, TR 
3.1 ms, TE 1.2 ms
LV, dimensions and function
LGE 4C, 2C, 3C, SAX (10 min)
8 mm ST, 2 mm gap, matrix 208x256, FOV
300x400, flip angle 30°, TR 2xRR interval, 
TE 4.9 ms, TI 220-290 ms
IS (FWMH), MVO (hypoenhancement)
Gadolinium contrast 0.2 mmol/kg
(gadopentate)
Mins
0
10
20
30
40
Pulse sequence parameters for Siemens scanners given. 4/3/2C ¼ 4/3/2-chamber long-axis; AAR ¼ area at risk; CMR ¼ cardiovascular magnetic resonance;
FWHM ¼ full-width half-maximum; FOV ¼ ﬁeld of view; IMH ¼ intramyocardial hemorrhage; IS ¼ infarct size; LGE ¼ late gadolinium-enhanced; LV ¼ left
ventricular; MVO¼microvascular obstruction; SAX¼ short-axis; ST ¼ slice thickness; T2w-STIR¼ T2-weighted short tau inversion recovery; TE ¼ echo time;
TI ¼ inversion time; TR ¼ repetition time.
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Additional secondary endpoints included cardiovascular
death, individual components of the primary endpoint,
and the safety endpoints stroke, major bleeding, and
contrast-induced nephropathy. Data were collected by an
independent clinical trials unit (Royal Brompton Hospital,
London, England) and events adjudicated by blinded
clinicians.
STATISTICAL ANALYSIS. The primary outcome was
infarct size (expressed as a % of LV mass) on
pre-discharge CMR, which was analyzed on a
log-transformed scale, as it is generally right-skewed.
Primary analysis was on an intention-to-treat basis of
all randomized patients according to treatment group
who completed the pre-discharge CMR. The result
was adjusted for known predictors of infarct size (age,
anterior MI, time to revascularization, diabetes, AAR,
Rentrop grade, and TIMI ﬂow grade pre-PPCI), using
generalized mixed models. No adjustments for mul-
tiplicity were performed for secondary endpoints.
Normally distributed continuous variables were
expressed as mean  SD, and comparison was with
Student t tests. Non-normally distributed data were
expressed as median (25th to 75th quartiles) andanalyzed using independent Student t testing where
log transformation normalized data, and using
Mann-Whitney testing were the degree of skew
rendered data nontransformable. Categorical vari-
ables were compared using chi-square testing. Clin-
ical outcomes were assessed using time-to-ﬁrst-event
survival analysis (log-rank test with right censoring),
and Cox proportional hazard models were ﬁtted to
estimate hazard ratios and 95% conﬁdence intervals
for treatment comparisons. One hundred patients in
each arm gave 81% power to detect a 4% absolute
difference in infarct size, assuming a mean of 20% of
LV mass and standard deviation of 10% (19,20), using
a 2-tailed test with alpha ¼ 0.05. New infarct
comprising 4% of LV mass is associated with adverse
prognosis in patients with revascularization-related
injury (21).
RESULTS
PATIENTS. In the CMR substudy, 205 consented to
participate. Of these, 2 patients were excluded: 1
patient did not complete the early CMR, and in 1 pa-
tient, the LGE images were not analyzable. The
TABLE 2 Periprocedural Details in the CR and IRA-Only Groups
CR
(n ¼ 98)
IRA
(n ¼ 105) p Value
Radial access 81/97 (83.5) 82/105 (78.1) 0.33
Symptom to PCI time, min* 192 (131–302) 172 (127–268) 0.20
Glycoprotein IIb/IIIa inhibitor 34/97 (35.1) 36/104 (34.6) 0.95
Bivalirudin 52/92 (56.5) 43/94 (45.7) 0.14
Thrombectomy catheter 67/97 (69.1) 79/105 (75.2) 0.33
Contrast dose, ml* 300 (220–400) 190 (150–230) <0.001
Screening time, min* 17 (12–23) 9 (7–13) <0.001
Procedure length, min* 66 (43–84) 42 (30–55) <0.001
Vessels with $70% stenosis 1.8  0.6 1.7  0.6 0.82
Left anterior descending IRA 34/98 (34.7) 39/105 (37.1) 0.82
Left circumﬂex artery IRA 20/98 (20.4) 18/105 (17.1) 0.55
Right coronary artery IRA 44/98 (44.9) 48/105 (45.7) 0.91
Rentrop grade
0–1 88/98 (89.8) 102/105 (97.1)
2–3 10/98 (10.2) 3/105 (2.9) 0.033
TIMI pre-PCI grade 0 (0–1) 0 (0–1) 0.56
TIMI grade post-PCI 3 (3–3) 3 (3–3) 0.31
IRA no-reﬂow 8/98 (8.2) 3/107 (2.8) 0.09
Total number of stents 3 (2–4) 1 (1–2) <0.001
Drug-eluting stent use 97/98 (99) 96/105 (91.4) 0.013
Aspirin 97/98 (99.0) 105/105 (100) 0.30
Second antiplatelet agent 98/98 (100) 105/105 (100) 1.00
Clopidogrel 34/98 (34.7) 36/105 (34.3) 0.95
Prasugrel 49/98 (50.0) 53/104 (51.0) 0.89
Ticagrelor 15/98 (15.3) 16/105 (14.3) 0.91
Beta-blocker 93/98 (94.9) 97/105 (92.4) 0.46
ACEI or ARB 95/98 (96.9) 101/105 (96.2) 0.77
Additional antianginal medication 6/98 (6.1) 17/105 (16.2) 0.024
Statin 98/98 (100) 104/105 (99.1) 0.33
Loop diuretic 9/98 (9.2) 13/105 (12.4) 0.46
Aldosterone inhibitor 5/98 (5.1) 5/105 (4.8) 0.91
Values are n/N (%), median (interquartile range), or mean  SD. The bold type indicates statis-
tically signiﬁcant p values. Additional antianginal medication includes calcium-channel blockers,
nitrates, or nicorandil. *Non-normally distributed data: analyzed after log transformation with
independent Student t testing.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; TIMI ¼
Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
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the CMR substudy were well-matched for character-
istics, with no statistically signiﬁcant differences
between groups, although there was a trend for more
women in the IRA-only group (Table 1).
ANGIOGRAPHIC AND PCI DETAILS. Data are shown
in Table 2. Thirty patients in the complete revascu-
larization group had a staged procedure 1.43 (inter-
quartile range [IQR]: 1.03 to 2.04) days after the
PPCI. Coronary artery disease severity was similar in
the groups, although the IRA-territory collateraliza-
tion grade was signiﬁcantly higher in the complete
revascularization group. Total screening time,
contrast dose, procedure length, and number of
implanted stents were signiﬁcantly greater incomplete revascularization patients. The vast ma-
jority of patients in both arms received drug-eluting
stents, although this was slightly higher in complete
revascularization patients. Symptom-to-PCI times,
antiplatelet, anticoagulant use, and post-PPCI
creatine kinase rise were similar in both arms.
There was a nonsigniﬁcant trend for no-reﬂow to be
more common in the complete revascularization
than the IRA group. There was greater usage of a
second antianginal agent in patients in the IRA-only
group.
PRE-DISCHARGE CMR. Results are displayed in
Table 3. Pre-discharge CMR was undertaken at a me-
dian of 3 days post-PPCI in both treatment arms.
There was no statistical difference in the primary
endpoint of total infarct size between the groups:
IRA-only, 13.5% (IQR: 6.2% to 21.9%) of LV mass
versus complete revascularization, 12.6% (IQR: 7.2%
to 22.6%) of LV mass, p ¼ 0.57. The ratio of the
geometric means for total infarct size in the IRA-only
(15.9  13.2%) and CR (16.3  13.0%) arms is 0.98 (95%
conﬁdence interval: 0.82 to 1.41), conﬁrming no dif-
ference between the 2 treatment arms. When cor-
rected for covariates (age, sex, anterior MI, time to
revascularization, TIMI ﬂow pre-PCI, diabetic status,
Rentrop grade and AAR), there remained no differ-
ence in median infarct size (beta ¼ 0.02, p ¼ 0.68)
between the 2 groups.
The prevalence of multiple territory infarcts in the
complete revascularization group was double that of
the IRA-only group and the number of acute non-IRA
infarcts was increased 3-fold in those undergoing
complete revascularization (Table 3). Examples, with
corresponding edema images, are shown in Figure 3,
and the location, size of infarct, expected coronary
artery territory, and whether the individual patients
had an additional non-IRA PCI are shown in Online
Table 1. Eighteen of 20 acute non-IRA infarcts in
patents in the complete revascularization group
concurred with additional PCI in the relevant non-
IRA coronary territory. Five patients randomized to
the IRA-only group also had non-IRA acute MI. Two
of these patients had treatment crossover and
received non-IRA PCI. The ﬁrst crossover followed
ongoing ischemia post-PPCI and was associated with
non-IRA MI in the relevant territory. The second
crossover resulted from human error, and this patient
had a small non-IRA acute MI in the anteroseptum
but had non-IRA PCI of the circumﬂex artery. Six
patients in the IRA-only and 5 in the complete
revascularization group had chronic infarcts (evi-
denced by wall thinning). Excluding these patients
from the analysis did not affect the results (Online
Table 2).
TABLE 3 Pre-Discharge and Follow-Up CMR
Pre-Discharge CMR
CR
(n ¼ 98)
IRA
(n ¼ 105) p Value
Total infarct size, % LV mass* 12.6 (7.2–22.6),
16.3  13.0
13.5 (6.2–21.9),
15.9  13.2
0.57
Time from PPCI, days* 3.0 (2.0–4.3) 2.8 (1.8–3.4) 0.13
Infarct on LGE 95 (96.9) 95 (90.5) 0.06
Patients with >1 infarct 22 (22.4) 11 (10.5) 0.02
Patients >1 acute infarct 17 (17.1) 5 (4.8) 0.004
Number of acute infarcts in those
with >1 infarct†
2 (2–2),
2.2  0.4
2 (2–2)
2.0  0.0
0.60
IRA infarct size, % LV mass* 12.1 (7.0–21.4),
15.2  12.1
12.2 (6.2–21.2),
15.3  13.2
0.68
Total acute IS, % LV mass* 12.5 (7.0–22.0)
15.8  12.4
12.4 (6.2–21.6)
15.4  13.2
0.60
Acute NIRA infarct size, % LV
mass in those with >1 infarct†
2.5 (0.54–4.5),
3.2  3.3
2.1 (0.81–4.5),
2.5  1.9
0.004
Acute NIRA infarct size
(% LV mass, per infarct†)
1.4 (0.3–2.3),
1.6  1.5
1.0 (0.4–2.2),
1.3  1.0
0.94
Area at risk, % LV mass§ 32.2  11.8 36.0  12.9 0.06
MSI§ 58.5 (32.8–74.9) 60.5 (40.6–81.9) 0.14
MVO present 57/98 (58.2) 54/105 (51.4) 0.34
MVO, % LV mass† 0.19 (0.00–2.00) 0.08 (0.00–1.05) 0.63
IMH present§ 22/75 (29.3) 17/77 (22.1) 0.31
RV infarction 7/98 (7.1) 4/105 (3.8) 0.29
LVMI, g/m2* 52.3 (46.8–62.0) 52.2 (44.7–59.2) 0.33
LVEDVI, ml/m2* 89.7 (80.7–102) 90.7 (80.4–102) 0.64
LVESVI, ml/m2* 47.0 (38.0–58.4) 49.8 (39.7–62.1) 0.56
LVEF, % 45.9  9.9 45.1  9.5 0.60
Follow-Up CMR (n ¼ 84) (n ¼ 80)
Time to CMR, months 9.4 (9.0–10) 9.3 (8.9–9.9) 0.20
LVMI, g/m2* 47.4 (40–52.6) 43.4 (38.0–49.3) 0.33
LVEDVI, ml/m2* 93.3 (82.2–110) 95.0 (82.7–107) 0.63
LVESVI, ml/m2* 45.1 (37.8–58) 43.6 (34.8–57.9) 0.33
LVEF, % 49.7  9.4 50.8  8.7 0.42
Infarct on LGE 82/84 (97.6) 71/80 (88.8) 0.023
Patients with >1 infarct 20/84 (23.8) 9/80 (11.2) 0.035
IS, % LV mass* 7.3 (3.0–14.4) 7.6 (3.2–15.1) 0.41
Final MSI* 82.1 (63.0–90.3) 79.4 (71.6–93.3) 0.20
Perfusion (n ¼ 82) (n ¼ 77)
Ischemic burden, %‡ 3.4  8.9 4.3  11.3 0.81
Ischemia present 17/82 (20.7) 16/77 (20.8) 0.99
Ischemic burden in patients
with ischemia, %
15.5  13.7 20.4  17.1 0.37
Ischemic burden >20% 6 (7.3) 6 (7.8) 0.91
Values are n/N (%), median (interquartile range), mean  SD, or n (%), unless otherwise noted. The bold type
indicates statistically signiﬁcant p values. *Nonnormally distributed data: analyzed after log transformation with
independent Student t testing. †Nonnormally distributed data: analyzed using Mann-Whitney analysis. ‡Because
the median and interquartile range was 0 (0 to 0) for both IRA and CR groups, mean  SD of the results are
presented although the data are nonparametrically distributed. §Analyzable edema imaging available in 75 of the
complete revascularization group and 77 of the IRA-only group.
IMH ¼ intramyocardial hemorrhage; IS ¼ infarct size; LGE ¼ late gadolinium enhancement; LV ¼ left ven-
tricular; LVEDVI ¼ left ventricular end-diastolic volume index; LVEF ¼ left ventricular ejection fraction; LVESVI ¼
left ventricular end-systolic volume index; LVMI ¼ left ventricular mass index; MSI ¼ myocardial salvage index;
MVO ¼ microvascular obstruction; NIRA ¼ non–infarct-related artery; PPCI ¼ primary percutaneous coronary
intervention; RV ¼ right ventricular; other abbreviations as in Table 1.
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2719MVO was present in more than one-half of all pa-
tients, although quantitatively, the amount was very
low (median <0.2% of LV mass). In 52 patients (26%),
AAR could not be quantiﬁed: no artifact, but no
edema discernable (n ¼ 33); not performed due to
arrhythmia or suboptimal breath-holding (n ¼ 14); or
severe artifact (n ¼ 5). AAR and MSI were lower, but
not signiﬁcantly, in the complete revascularization
group. LV volume, mass, and ejection fraction were
similar in both groups.
FOLLOW-UP CMR. Follow-up CMR was completed in
84 patients in the complete revascularization group
and 80 patients in the IRA-only group (Table 3). Of the
39 patients who did not have a repeat CMR, 29 pa-
tients declined, 3 had died, 2 cited claustrophobia, 1
had an implantable cardioverter-deﬁbrillator, 1 had a
severe noncardiovascular illness, and in 3, there were
logistical reasons. There were no differences in
baseline characteristics or pre-discharge CMR be-
tween those who completed and did not attend the
follow-up CMR (data not shown). Three patients were
unable to undertake adenosine stress perfusion due
to obstructive airways disease, and perfusion imaging
was unanalyzable in 2 patients due to severe persis-
tent dark-rim artefact (1 in the complete revasculari-
zation group, 1 in the IRA-only group). LV volumes
and function were similar between groups. The
prevalence of infarct and multiple infarcts were
greater in the complete revascularization group.
However, there was no signiﬁcant difference in total
infarct size and ﬁnal MSI between the groups.
Reversible perfusion defects were seen in 21% of pa-
tients in both groups, and overall ischemic burden
was small. When the extent of ischemia was assessed
only in patients with reversible perfusion defects, the
ischemic burden was not statistically different in the
complete revascularization and IRA-only groups.
CLINICAL OUTCOMES. Median follow-up was 372
days (IRA 377 days, complete revascularization 366
days, p ¼ 0.38). One hundred ninety-eight (98%) pa-
tients attended 12-month clinical follow-up (3 patients
died before this time point, and 2 patients withdrew
consent). Length of inpatient stay and incidence of
in-hospital clinical events were similar in the treat-
ment arms (Table 4). There was a borderline signiﬁcant
reduction in MACE in patients undergoing complete
revascularization, and the corresponding events rates
and hazard ratio were similar to that seen in the main
trial. Thirteen patients in the IRA-only arm had 14
revascularization procedures (2 separate PCIs in 1 pa-
tient) after PPCI. All but 1 were revascularization to the
non-IRAs (1 patient had acute stent thrombosis of the
IRA on day 0 and had repeat PCI). The indications wereas follows: acute coronary syndrome 7 (3 non-STEMI);
6 refractory symptoms (1 coronary artery bypass sur-
gery); and 1 patient underwent elective PCI at the
discretion of the responsible physician.
FIGURE 3 Examples of Patients With >1 “Acute” MI on CMR
Late gadolinium-enhanced short-axis images (top row and third rows) and corresponding colocalized edema images (second and fourth rows).
Red asterisks indicate IRA-territory infarct; blue asterisks indicate NIRA-territory infarct(s). Subject ID: (A) (X511); (B) (X612); (C) (X665); (D)
(X709); (E) (X757); (F) (X791); (G) (X798); (H) (X808). IRA infarct size and non-IRA PCI are shown in Online Table 1. NIRA ¼ non–infarct-related
artery; other abbreviations as in Figure 2.
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2720DISCUSSION
This is the ﬁrst detailed study of pre-discharge and
follow-up CMR outcomes in a randomized study
of IRA-only versus complete revascularization in
multivessel coronary disease at PPCI. The data have
conﬁrmed that non-IRA PCI is associated with addi-
tional infarction. However, these type 4a MIs (6) are
relatively infrequent, generally small, and did not
result in an increase in total infarct size. There is
mounting evidence from randomized trials that
treating multivessel disease with complete revascu-
larization (4,22) leads to a reduction in MACE after
PPCI compared with an IRA-only strategy.The patients in the substudy had similar baseline
characteristics to those in the main trial. Because time
to revascularization (4) and anterior MI (23) are
strongly associated with infarct size, randomization
was stratiﬁed by these variables. There was a similar
reduction in the hazard ratio for MACE in the com-
plete revascularization CMR subgroup as that seen in
the main study compared with IRA-only revasculari-
zation, and we believe that the CMR substudy popu-
lation is representative of those in the main study.
It is well-recognized that elective PCI can cause a
troponin rise in approximately 30% of patients and
approximately 50% undergoing PCI for unstable
angina (24). Such type 4a MIs (6) can be detected on
TABLE 4 Clinical Outcomes
12-Month Follow-Up
CR
(n ¼ 98)
IRA
(n ¼ 105) HR (95% CI) p Value
MACE 8 (8.2) 18 (17.1) 0.43 (0.18–1.04) 0.055
Death 1 (1.0) 1 (1.0) 1.07 (0.07–17.4) 0.96
Recurrent MI 0 (0.0) 3 (2.9) — 0.10
Heart failure 3 (3.1) 4 (3.8) 0.80 (0.17–3.7) 0.77
Revascularization 4 (4.1) 10 (9.5) 0.40 (0.12–1.3) 0.13
Inpatient Clinical Events OR (95% CI)
Length of inpatient
stay, days
3 (2–4),
3.5  2.6
3 (2–4),
3.9  2.8
0.13
Death 1 (1.0) 1 (0.9) 1.07 (0.07–17.4) 0.96
Recurrent MI 0 (0.0) 1 (0.9) 2.17 (0.19–24.3) 0.33
Heart failure 2 (2.0) 1 (1.0) 0.71 (0.12–4.3) 0.52
Repeat revascularization 2 (2.0) 3 (2.9) — 0.71
Safety endpoints
Contrast nephropathy 1 (1.0) 0 (0.0) — 0.30
Vascular access injury
needing repair
0 (0.0) 0 (0.0) — 1.00
CVA/TIA 0 (0.0) 0 (0.0) — 1.00
Major bleed 3 (3.1) 1 (1.0) 3.29 (0.34–32.1) 0.28
Values are n (%), median (interquartile range), or mean  SD. A dash indicates that no HR was presentable
because 1 or both treatment arms had an incidence of 0.
CI ¼ conﬁdence interval; CVA ¼ cerebrovascular accident; HF ¼ heart failure; HR ¼ hazard ratio; MACE¼major
adverse cardiovascular events; OR ¼ odds ratio; TIA ¼ transient ischemic attack; other abbreviations as in Table 1.
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2721CMR and have been associated with adverse prog-
nosis (21,25). In this substudy of CvLPRIT, the prev-
alence of >1 CMR-detected infarct in patients
receiving complete revascularization was double that
in the IRA-only arm (23.8% vs. 11.2%), and more than
3-fold for the acute non-IRA infarcts (17.1% vs. 4.8%)
(Central Illustration). Previous Q-wave MI was an
exclusion criterion in this study, but 4% had a history
of previous non-STEMI, and a similar number (6% in
the IRA-only and 5% in the complete revasculariza-
tion groups) had chronic non-IRA MI on the pre-
discharge CMR. Excluding these patients did not
signiﬁcantly affect the results. These data suggest
that an additional 12% of patients with multivessel
disease who receive complete revascularization at the
time of PPCI will have evidence of additional CMR-
detectable infarction compared with IRA-only revas-
cularization. However, this proportion is less than
might have been expected from previous studies in
elective PCI (24), where up to 29% of patients have
evidence of new infarction on CMR associated with
troponin elevation (25). The extent of acute non-IRA
infarction was also smaller (median 2.5% of LV
mass) than may have been anticipated from elective
PCI data given that average infarct size in those with
new late enhancement on CMR was 5.0  4.8% of
LV mass (25), despite all patients in that study being
pre-treated with clopidogrel for >24 h and given a
glycoprotein IIb/IIIa inhibitor periprocedurally.
Importantly, in the present study, total infarct size
was not increased in the short term or at follow-up,
and there were no signiﬁcant differences in myocar-
dial salvage, LV volumes, or ejection fraction between
the treatment groups. Peak creatine kinase levels
were also similar in the 2 groups.
These ﬁndings provide reassurance that non-IRA
intervention at the time of PPCI does not lead to
increased total infarct size. In the main CvLPRIT trial,
complete revascularization resulted in a signiﬁcantly
reduced hazard ratio for 12-month MACE despite the
greater prevalence of CMR-detected type 4a MIs
shown here. There are limited data as to whether
revascularization-induced myocardial injury detected
by CMR is linked to prognosis (21), and none in
patients presenting with STEMI. In an observational
study of 152 patients undergoing elective revascular-
ization, 32% had evidence of new LGE, which aver-
aged 5 g (4% of LV mass), and one-half of these
patients were treated with coronary artery bypass
surgery (21). In that study, patients with new infarc-
tion following revascularization had reduced ejection
fraction, increased LV volume, increased total infarct
size, and a 3-fold increase in MACE at a median of 2.9
years follow-up compared with those without newLGE (21). Given that the complete revascularization
group in the current study had no increase in total
infarct size, LV volume, or reduced ejection fraction,
it seems unlikely that the short- to medium-term
clinical beneﬁts of complete revascularization (22)
will be offset in the long term by increased heart
failure or sudden cardiac deaths. However, longer-
term follow-up of patients in this study is needed to
conﬁrm this.
We did not observe any signiﬁcant differences in
myocardial salvage between the treatment groups
in this study. Non-IRA revascularization at the time
of PPCI could increase perfusion to watershed
areas by relieving ﬂow-limiting stenoses, resulting
in increased myocardial salvage (26). Alternatively,
resting myocardial perfusion and ﬂow reserve
following PCI may actually be reduced, as has been
shown in elective patients as a result of distal
embolization, particularly when the PCI is associated
with new LGE (26,27). It may be that both effects are
seen with non-IRA PCI resulting in no net beneﬁt with
regard to myocardial salvage in the PPCI setting.
Unexpectedly, we also observed no difference in
ischemic burden between the groups undergoing
follow-up stress perfusion CMR. There are several
potential explanations for this ﬁnding. First, it is
well recognized that even severe angiographic ste-
noses may not cause ischemia (28,29). Second, 11
patients in the IRA-only arm had further PCI before
CENTRAL ILLUSTRATION Complete Versus Lesion-Only Revascularization in Acute MI: The CMR CvLPRIT Substudy
CMR Infarcts                                                      CR                                p                            IRA-only
Acute N-IRA MI
Leave N-IRAN-IRA Stenoses
Artery (N-IRA)
17/98 (17.1%) 0.004 5/103 (4.8%)
Total IS (% LV Mass)                                      12.6 (7.2-22.6)                    0.57                        13.5 (6.2-21.9)
IRA IS (% LV Mass)                                          12.1 (7.0-21.4)                    0.68                        12.2 (6.2-21.2)
*
*
Pre-Discharge CMR-Day 2-3
Occluded
Infarct Related
Artery (IRA)
McCann, G.P. et al. J Am Coll Cardiol. 2015; 66(24):2713–24.
Overview of the CvLPRIT CMR trial showing the randomization strategy and main results. Red asterisk indicates IRA late gadolinium enhancement; blue asterisk
indicates N-IRA late gadolinium enhancement. CMR ¼ cardiovascular magnetic resonance; CvLPRIT ¼ Complete Versus Lesion-Only Primary PCI Pilot Study; LV ¼ left
ventricular; MI ¼ myocardial infarction; N-IRA ¼ non–infarct-related artery; IS ¼ infarct size.
McCann et al. J A C C V O L . 6 6 , N O . 2 4 , 2 0 1 5
The CvLPRIT CMR Substudy D E C E M B E R 2 2 , 2 0 1 5 : 2 7 1 3 – 2 4
2722the stress CMR that is likely to have reduced
ischemic burden in this group. Third, the small
number of crossovers from randomization is likely to
have diminished the differences in ischemia be-
tween the groups. Finally, the stress CMR was un-
dertaken in patients on optimal medical therapy,
which may dramatically reduce post-MI ischemia
(30) making it more difﬁcult to detect differencesbetween the groups, especially as there was higher
use of a second antianginal medication in the IRA-
only group. This may also explain why the overall
ischemic burden in our study was small (3% to 4%).
It remains to be determined whether ischemia is
prognostically important in the PPCI era, especially
because medical therapy may result in similar clin-
ical outcomes to a revascularization strategy even in
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In patients with
STEMI and multivessel disease, a strategy of complete revascu-
larization is associated with a small increase (12%) in the risk of
type 4a MIs, but similar total infarct size, compared with a
strategy addressing only the infarct-related artery.
TRANSLATIONAL OUTLOOK: Future trials should incorpo-
rate selective revascularization strategies based on coronary
angiography at the time of primary PCI and functional as-
sessments of coronary lesions to guide complete
revascularization.
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2723patients treated with thrombolysis (30). Further
insight on this subject will be available from the
CvLPRIT nuclear substudy.
STUDY LIMITATIONS. The optimal timing to assess
infarct size post-STEMI is uncertain (31). We chose
an early time point to enhance participation in the
CMR substudy because we felt there could have been
a higher dropout rate scanning patients after hospi-
tal discharge. MSI was only reliably measured in
w75% of patients, and the use of novel T1 or T2
mapping techniques for future studies may lead to a
more robust assessment. Current CMR techniques
cannot reliably differentiate whether a very small
MI, which is not associated with wall thinning,
edema, or MVO, is acute or chronic, and this
contributed to the slight overreporting of acute
non-IRA MIs that were not associated with revascu-
larization in this study.
CONCLUSIONS
An in-hospital complete revascularization strategy
in patients with multivessel disease at the time
of PPCI is associated with a small increase in type
4a MIs in non-IRA territories, but total infarct sizewas not signiﬁcantly different compared with an
IRA-only strategy.
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